Repositioning Candidate Details
| Candidate ID: | R0380 |
| Source ID: | DB01034 |
| Source Type: | experimental |
| Compound Type: | small molecule |
| Compound Name: | Cerulenin |
| Synonyms: | (2R,3S)-3-((4E,7E)-Nona-4,7-dienoyl)-oxirane-2-carboxylic acid amide; (2R,3S)-3-((4E,7E)-nona-4,7-dienoyl)oxirane-2-carboxamide; Cerulenin |
| Molecular Formula: | C12H17NO3 |
| SMILES: | [H][C@]1(O[C@]1([H])C(=O)CC\C=C\C\C=C\C)C(N)=O |
| Structure: |
|
| DrugBank Description: | Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols. In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus. |
| CAS Number: | 17397-89-6 |
| Molecular Weight: | 223.272 |
| DrugBank Indication: | For use as a biochemical tool, Cerulenin is shown to cause dramatic weight loss in animals |
| DrugBank Pharmacology: | Cerulenin is an antifungal antibiotic isolated from <i>Cephalosporium caerulens</i>. It interrupts fungal growth by inhibiting the biosynthesis of sterols and fatty acids (inhibits bacterial fatty acid synthesis). It also inhibits HMG-CoA synthetase activity. Cerulenin produces metabolic effects similar to effects of leptin, but through mechanisms that are independent of, or down-stream from, both leptin and melanocortin receptors. |
| DrugBank MoA: | Irreversibly binds to fatty acid synthase, specifically b-ketoacyl-acyl carrier protein synthase (FabH, FabB and FabF condensation enzymes). A number of tumor cells and cell lines have been observed to have highly upregulated expression and activity of fatty acid synthase (FAS). Inhibition of FAS by cerulenin leads to cytotoxicity and apoptosis in human cancer cell lines, an effect believed to be mediated by the accumulation of malonyl-coenzyme A in cells with an upregulated FAS pathway. |
| Targets: | 3-oxoacyl-[acyl-carrier-protein] synthase 1 inhibitor; 3-oxoacyl-[acyl-carrier-protein] synthase 2 inhibitor; 3-oxoacyl-[acyl-carrier-protein] synthase 3 inhibitor; Fatty acid synthase inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S08 | Lifestyle measures | Lifestyle intervention; weight loss; diet adaptation; dietary interventions; lifestyle modifications; Exercise | -- | -- | Details |
| S13 | Anti-apoptosis | hepatocyte apoptosis; hepatic autophagy; apoptosis | Pan-caspase inhibitor | Emricasan | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|